AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6107136
Drug: Propranolol at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol at a dose level of 1,280‐1,920 mg per day
Trial: 28958651
Drug: 0.23% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.23% ropivacaine at 5 ml/h
Trial: 28958651
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline at 5 ml/h
Trial: 26945812
Drug: Low-fat milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat milk consumption (200 mL twice daily for 6 weeks)
Trial: 22385444
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (Group B)
Trial: 17714607
Drug: Ciclesonide 160
RxNorm normalized name: CICLESONIDE 160MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 160 microg once daily (CIC160 OD)
Trial: 17714607
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 250 microg twice daily (FP250 BID)
Trial: 12920059
Drug: CCK octapeptide
RxNorm normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK octapeptide (CCK-8; 112 ng/min for 23 min) with gastric distension (300 ml)
Trial: 12920059
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion with gastric distension (300 ml)
Trial: 12920059
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion without gastric distension
Trial: 12920059
Drug: Gastric distension
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric distension (300 ml) without CCK
Trial: 11938830
Drug: Xiangsha Yangwei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiangsha Yangwei pill (XSYW)
Trial: 8265515
Drug: ICI 169,369
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 169,369 30 mg
Trial: 8265515
Drug: ICI 169,369
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 169,369 120 mg
Trial: 24933175
Drug: Sequential photo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential photo lineup procedure
Trial: 24933175
Drug: Both procedures
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both procedures (simultaneous and sequential)
Trial: 3307499
Drug: Oral fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fructose mineral drink
Trial: 28530532
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy for 8 weeks
Trial: 15678363
Drug: Caffeine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (75 mg)
Trial: 25761837
Drug: Caffeine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (75 mg) + L-theanine (50 mg)
Trial: 25761837
Drug: L-theanine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine (50 mg)
Trial: 21114493
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 at a dose of 1 × 10(8) CFU per day for 30 days
Trial: 7528299
Drug: nitrendipine (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrendipine (10‐20 mg b.i.d.)
Trial: 7528299
Drug: captopril (25‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril (25‐50 mg b.i.d.)
Trial: 3053569
Drug: Spiramycin tablets
RxNorm normalized name: spiramycin
DrugBank: Spiramycin (DB06145)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Spiramycin tablets for 5 1/2 days
Trial: 3053569
Drug: Doxycycline tablets
RxNorm normalized name: Doxycycline Tablets
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline tablets for nine days
Trial: 19632716
Drug: Concurrent induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent induction chemotherapy (two cycles of cisplatin [50 mg/m(2) on days 1, 8, 29, and 36] and etoposide [50 mg/m(2) on days 1‐5 and 29‐33]) plus radiotherapy (45 Gy) followed by surgical resection if no progression.
Trial: 19632716
Drug: Standard concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard concurrent chemotherapy and definitive radiotherapy without resection (up to 61 Gy).
Trial: 19632716
Drug: Concurrent induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent induction chemotherapy plus radiotherapy followed by surgical resection.
Trial: 19632716
Drug: Standard concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard concurrent chemotherapy and definitive radiotherapy without resection.
Trial: 16541859
Drug: Acupuncture kinetotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture kinetotherapy (Acupuncture at Kaiyin point No. 1 combined with deep respiratory movement of the glottis), once daily for 5 days
Trial: 16541859
Drug: Ultrasonic aerosol
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasonic aerosol inhalation of 0.9% sodium chloride injection, gentamicin sulfate injection 80,000 U and Dexamethasone injection 5mg, twice a day for 5 days
Trial: 9075040
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 3 micrograms/kg
Trial: 9075040
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 4 micrograms/kg
Trial: 30014865
Drug: High flavonoid
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavonoid cocoa drink (350 mg gallic acid equivalents {GAE}/g)
Trial: 30014865
Drug: Low flavonoid
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flavonoid cocoa control (120 mg GAE/g)
Trial: 23571810
Drug: ABT‐925 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐925 150 mg
Trial: 23571810
Drug: ABT‐925 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐925 50 mg
Trial: 18844328
Drug: Yamabushitake (Hericium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yamabushitake (Hericium erinaceus) - 250 mg tablets, 4 tablets three times a day for 16 weeks
Trial: 11741100
Drug: Cabergoline, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline, a long-acting dopamine agonist, dosage and duration not specified
Trial: 11741100
Drug: Levodopa, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa, a dopaminergic agent, dosage and duration not specified
Trial: 9682673
Drug: Half-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose aprotinin (Group 2)
Trial: 9682673
Drug: Full-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose aprotinin (Group 3)
Trial: 8161288
Drug: Oral fluphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluphenazine hydrochloride (5 mg twice daily)
Trial: 29669963
Drug: Intravenous Nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Nicorandil
Trial: 27549626
Drug: Vaccine-primed group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-primed group (VP)
Trial: 18371483
Drug: Estimated GFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimated GFR <60 mL/min
Trial: 16618300
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of tropisetron (0.1 mg x kg(‐1), max 2 mg) immediately after inhalational induction
Trial: 16618300
Drug: Late administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late administration of tropisetron (0.1 mg x kg(‐1), max 2 mg) after the end of surgery before extubation
Trial: 16618300
Drug: Late administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late administration of tropisetron
Trial: 16618300
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of tropisetron
Trial: 16618300
Drug: Both early
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both early and late administration of tropisetron
Trial: 11007220
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg t.i.d. for 30 days
Trial: 8831847
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antibiotic suspension only)
Trial: 8173689
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of felodipine plus metoprolol 5/50‐10/100 mg (FM)
Trial: 8173689
Drug: Felodipine 5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5‐10 mg (F)
Trial: 8173689
Drug: Metoprolol 50‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50‐100 mg (M)
Trial: 3527886
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LH); n = 29
Trial: 3527886
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH); n = 27
Trial: 27189681
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate (25 mg/kg, intravenous, single dose)
Trial: 27189681
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (single dose)
Trial: 24059690
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg once daily (titrated to 100 mg for non-responders)
Trial: 23420326
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (group M) treated with pioglitazone
Trial: 23420326
Drug: Gallstone group
RxNorm normalized name: Bos taurus gallstone preparation
DrugBank: Bos taurus gallstone (DB14248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallstone group (group G)
Trial: 16324915
Drug: Glimepiride +
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride + 4 mg rosiglitazone
Trial: 16324915
Drug: Glimepiride +
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride + 8 mg rosiglitazone
Trial: 14653829
Drug: Artichoke leaf
RxNorm normalized name: artichoke leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artichoke leaf extract (ALE) 2 x 320 mg plant extract t.d.s.
Trial: 8971428
Drug: Theophylline (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (loading dose 5 mg kg‐1 over 20 min, followed by 0.5 mg kg‐1 min‐1)
Trial: 8971428
Drug: Dipyridamole (0.21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (0.21 mg kg‐1 h‐1)
Trial: 1317691
Drug: Thiorphan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiorphan (2.5 mg/ml, 0.5 ml)
Trial: 6742538
Drug: Flunitrazepam (0.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (0.33 mg X kg‐1)
Trial: 6742538
Drug: Midazolam (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.3 mg X kg‐1)
Trial: 6742538
Drug: Midazolam (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.4 mg X kg‐1)
Trial: 29670416
Drug: Intravenous Oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Oxycodone
Trial: 30875090
Drug: Intravenous Sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Sufentanil
Trial: 24780450
Drug: Tight glycaemic
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycaemic control (TGC): insulin by intravenous infusion titrated to maintain blood glucose between 4.0 and 7.0 mmol/l.
Trial: 24780450
Drug: Conventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional management (CM): insulin by intravenous infusion only if blood glucose exceeded 12.0 mmol/l on two samples at least 30 minutes apart; insulin was stopped when blood glucose fell below 10.0 mmol/l.
Trial: 22855332
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg twice a day)
Trial: 20532723
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 3 mg/kg/hr infusion)
Trial: 20388468
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine interventions
Trial: 12492906
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg CHX 2 x daily for 30 s (0.1% CHX)
Trial: 12492906
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg CHX 2 x daily for 60 s (0.06% CHX)
Trial: 12492906
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml SFAF rinse 1 x daily for 30 s
Trial: 12492906
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg CHX 2 x daily for 30 s (0.06% CHX)
Trial: 12492906
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml placebo 2 x daily for 60 s
Trial: 8525690
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine administered at 0, 2, and 6 months of age
Trial: 8525690
Drug: DTP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP and oral polio vaccines
Trial: 8525690
Drug: Polio vaccine
RxNorm normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polio vaccine
Trial: 8525690
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine with DTP and polio vaccines
Trial: 2359570
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (500 mg three times daily during menses)
Trial: 2359570
Drug: Norethisterone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone (5 mg twice daily on days 19-26 of the cycle)
Trial: 27486204
Drug: Azithromycin (AZM)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZM) 250 mg daily for 8 weeks
Trial: 21525260
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea polyphenols beverage providing 1402 mg total catechins/d
Trial: 21525260
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea polyphenols (0.5, 1.0, and 2.0 g) in a separate study
Trial: 16537867
Drug: Heliox inhalation
RxNorm normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heliox inhalation for 1 hour
Trial: 16537867
Drug: Airox inhalation
RxNorm normalized name: Agkistrodon piscivorus antivenin / Crotalus adamanteus antivenin / Crotalus atrox antivenin / Crotalus scutulatus antivenin Injection [CroFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Airox inhalation for 1 hour
Trial: 10831074
Drug: i.v. mycophenolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. mycophenolate mofetil (MMF) 1 g Q12h
Trial: 10831074
Drug: i.v. mycophenolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. mycophenolate mofetil (MMF) 1 g b.i.d.
Trial: 9085956
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine (3 mg/kg)
Trial: 9085956
Drug: 0.25% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% lidocaine (1.5 mg/kg) with 1 microg/kg of fentanyl and 0.5 mg of pancuronium
Trial: 8025983
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg daily)
Trial: 3028660
Drug: Ifosfamide administered
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide administered with mesna (IFO/M)
Trial: 25055491
Drug: Propofol (0.3‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.3‐2 mg/kg per hour)
Trial: 22079736
Drug: Hypofractionated radiotherapy
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiotherapy combined with long-term androgen deprivation therapy
Trial: 20535924
Drug: Periodontal initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Periodontal initial therapy together with Chinese herbal compound (TCM) for clearing heat and detoxification
Trial: 20535924
Drug: Periodontal initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Periodontal initial therapy alone (Control group)
Trial: 17214996
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg (C600)
Trial: 17214996
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg (C300)
Trial: 11819153
Drug: Idebenone 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone 360 mg/day
Trial: 11819153
Drug: Tacrine up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine up to 160 mg/day
Trial: 10566611
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy combinations
Trial: 10566611
Drug: Cisplatin with
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin with newer agents (vinorelbine or paclitaxel)
Trial: 8948920
Drug: Dinoprostone 0.5
RxNorm normalized name: dinoprostone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone 0.5 mg in gel form (intracervically applied)
Trial: 9659017
Drug: midazolam 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.08 mg.kg‐1
Trial: 2021987
Drug: morphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.15 mg.kg‐1 with perphenazine 2.5‐5.0 mg im
Trial: 7021431
Drug: Propiram 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiram 50 mg
Trial: 7021431
Drug: Propiram 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiram 100 mg
Trial: 31901794
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy for Suicide Prevention (CTSP) + Treatment as Usual (TAU)
Trial: 31347920
Drug: Hatha yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hatha yoga therapy (6 standardized 35-min weekly sessions)
Trial: 31347920
Drug: Conventional therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapeutic exercises (CTEs) (6 standardized 35-min weekly sessions)
Trial: 22537508
Drug: Hatha yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hatha yoga therapy
Trial: 23192725
Drug: Midazolam continuous
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam continuous infusion in hypothermic patients
Trial: 23192725
Drug: Midazolam as
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam as sedative in control group
Trial: 23192725
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of pharmacokinetics between groups
Trial: 22042783
Drug: FAC +
RxNorm normalized name: 4'-Thio-fac
DrugBank: 4'-Thio-fac (DB16071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC + G-CSF (5-FU 600 mg/m², doxorubicin 60 mg/m², cyclophosphamide 1000 mg/m² every 18 days for four cycles)
Trial: 22042783
Drug: FAC (5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC (5-FU 500 mg/m², doxorubicin 50 mg/m², cyclophosphamide 500 mg/m² every 21 days for four cycles)
Trial: 22042783
Drug: FAC +
RxNorm normalized name: 4'-Thio-fac
DrugBank: 4'-Thio-fac (DB16071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC + G-CSF
Trial: 10731301
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sulphur pool and bathing in the Dead Sea